Two Independent Mechanisms for Escaping Epidermal Growth Factor-mediated Growth Inhibition in Epidermal Growth Factor Receptor–hyperproducing Human Tumor Cells

Masamichi Hirai,* Shinobu Gamou,* Shinsei Minoshima,* and Nobuyoshi Shimizu**

*Department of Molecular Biology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160, Japan; and **Department of Molecular and Cellular Biology, University of Arizona, Tucson, Arizona 85721

Abstract. Human squamous cell carcinoma cell lines often possess increased levels of epidermal growth factor (EGF) receptor. The growth of these EGF receptor–hyperproducing cells is usually inhibited by EGF. To investigate the mechanism of EGF-mediated inhibition of cell growth, variants displaying alternate responses to EGF were isolated from two squamous cell carcinoma lines, NA and Ca9-22; these cell lines possess high numbers of the EGF receptor and an amplified EGF receptor (EGFR) gene. The variants were isolated from NA cells after several cycles of EGF treatment and they have acquired EGF-dependent growth. Scatchard plot analysis revealed a decreased level of EGF receptor in these ER variants as compared with parental NA cells. Southern blot analysis and RNA dot blot analysis demonstrated that the ER variants had lost the amplified EGFR gene. One variant isolated from Ca9-22 cells, CER-1, grew without being affected by EGF. CER-1 cells had higher numbers of EGF receptor than parental Ca9-22 but similar EGFR gene copy number. Flow cytometric analysis indicated an increase in ploidy and cell volume which may give rise to the increase in receptor number per cell. The EGF receptors on both Ca9-22 and CER-1 cells were autophosphorylated upon EGF exposure in a similar manner suggesting no obvious alteration in receptor tyrosine kinase. However, very efficient down-regulation of the EGF receptor occurred in CER-1 cells. These data suggest two independent mechanisms by which EGF receptor-hyperproducing cells escape EGF-mediated growth inhibition: one mechanism is common and involves the loss of the amplified EGFR genes, and another is novel and involves the efficient down-regulation of the cell-surface receptor.

Epidermal growth factor (EGF) is a potent mitogen for a variety of cells (Carpenter and Cohen, 1979). The mitogenic signal of EGF is transduced through its membrane-anchored glycoprotein receptor of Mr 170,000 (Cohen et al., 1982). The binding of EGF to the receptor induces a series of biochemical reactions including autophosphorylation of the EGF receptor (Cohen et al., 1980), clustering of the EGF receptor into coated pits (Schechter et al., 1979) and internalization and intracellular processing of the EGF/EGF receptor complex (Schlessinger et al., 1978; Hailer et al., 1978; Miskimins and Shimizu, 1984). Concurrently, cellular protein phosphorylation (Hunter and Cooper, 1981), c-fos and c-myc protooncogene expression (Müller et al., 1985) and phosphatidylinositol turnover (Sawyer and Cohen, 1981) are induced.

However, the presence of EGF at the concentrations mitogenic for other cells was found to be markedly inhibitory for the growth of the epidermoid carcinoma cell line A431 (Gill and Lazar, 1981; Barnes, 1982), which possesses extremely high numbers of the EGF receptor (Fabricant et al., 1977) as well as EGF receptor (EGFR) gene amplification (Lin et al., 1984; Ulrich et al., 1984). Similar growth inhibition has been reported for the breast cancer cell line MDA-468 (Filmus et al., 1987), which also possesses high numbers of the EGF receptor. To determine which biochemical response is crucial for growth inhibition of these cells and also for growth stimulation of cells with ordinary numbers of EGF receptor, we and others have isolated EGF-response variants using EGF (Buss et al., 1982; Bravo, 1984), EGF conjugated with the A subunit of ricin (Shimizu et al., 1984) and anti-EGF receptor antibody conjugated with the A subunit of ricin (Behzadian and Shimizu, 1985a). The correlation of growth inhibition with receptor concentration (Kawamoto et al., 1984), receptor tyrosine kinase activity (Buss et al., 1984), receptor metabolism (Lifshitz et al., 1983), protooncogene induction (Bravo et al., 1985) and phosphatidylinositol turnover (Behzadian and Shimizu, 1985a) was extensively studied in these variants. In most cases, the variants were found to contain reduced levels of EGF receptor (Filmus et al., 1987; Buss et al., 1982; Shimizu et al., 1984; Behzadian and Shimizu, 1985a), which seemed to be essential for escape.
Materials and Methods

Cell Culture

Squamous cell carcinoma cell lines (Yamamoto et al., 1986; Gamou et al., 1988) are kindly provided by Dr. K. Rikimaru (Tokyo Medical and Dental University, Tokyo, Japan). Cell lines were maintained in DME (Gibco, Grand Island, NY) supplemented with 10% FCS (Boehringer-Mannheim), kanamycin (100 µg/ml), Meiji, Tokyo, Japan) and fungizone (1 µg/ml). Squibb, Princeton, NJ) (DME/FCS/10 in 5% CO2 and 100% humidity at 37°C.

Variant Selection

NA and Ca9-22 cells grown in a 90-mm culture dish (>10° cells/dish) were treated with EGF (100 ng/ml; Toyobo [Osaka, Japan]; ultrapure grade) for 3 d and then transferred to 10 90-mm dishes. Fresh media containing EGF were added every 3 d for 1 mo. Several independent colonies which grew in the presence of EGF were isolated. To determine the growth rate of the cells, 5 × 10° cells were plated in 35-mm culture dishes containing DME/FCS/10. After 24 h of incubation, the media was replaced with media containing various concentrations of EGF. The cells were detached with trypsin/EDTA and counted with a hemocytometer.

[3H]-EGF-binding Assay

[3H]-EGF Binding was assayed as previously described (Gamou et al., 1984). To separate cell surface-bound EGF from intracellular EGF, cells which had been incubated with [3H]-EGF were treated for 1 min with 0.5 M NaCl/0.2 N acetic acid as described (Haigler et al., 1980). Then the cells were washed twice with 0.075 M KCl treatment and Cari- noy fixation. Karyotypes were analyzed after trypsin/Giemsa banding as described (Gill et al., 1985).

Rate of Receptor Biosynthesis

4 × 10° cells were plated in 35-mm dishes and incubated at 37°C for 2 d. Cells were treated with EGF (100 ng/ml) for the indicated times, washed twice with methionine-free DME (Microbiological Assocs.) and then labeled with [3S]methionine (80 µCi/ml, tran-[3S]-labeled, ICN) in methionine-free DME/FCS/10 for 30 min. After labeling, the EGF receptor was immunoprecipitated with B4G7 antibody bound to protein A-Sepharose and analyzed on SDS-PAGE as described previously (Gamou et al., 1987).

Receptor Phosphorylation

Confluent cells in 35-mm dishes were washed twice with phosphate-free minimum essential medium (MEM), then labeled with [3P]orthophosphate (2.5 mCi/ml, Amersham Corp., Arlington Heights, IL) in phosphate-free MEM for 1 h. EGF (200 ng/ml) was directly added to medium at 15 min before lysis. After labeling, the EGF receptors were immunoprecipitated with B4G7 and purified on SDS-PAGE as described previously (Gamou et al., 1987). Two-dimensional phosphopeptide mapping and phosphoamino acid analysis were performed as described previously (Beem and Hunter, 1978, Iwashita and Fox, 1984).

Results

Isolation of EGF Resistant Variants

Growth of the EGF receptor-hyperproducing A431 epidermoid carcinoma cell line was inhibited by EGF. Overproduction of EGF receptor to the same extent as A431 cells was often observed in squamous cell carcinoma lines (Yamamoto et al., 1986; Gamou et al., 1988). Thus, we first examined whether EGF-mediated growth inhibition is common in these EGF receptor-hyperproducing cell lines. As shown in Fig. 1, EGF inhibited the growth of the receptor-hyperproducing cell lines.

To investigate the mechanism of EGF-mediated inhibition of cell growth, variants showing alternate responses to EGF were isolated from two cell lines, NA and Ca9-22. These cell lines have a high number of EGF receptors (Table I) and an amplified EGFR gene; they are the most sensitive cell lines.
to EGF-mediated growth inhibition. Variants which grew after several cycles of EGF (100 ng/ml) treatment appeared at an approximate rate of $1 \times 10^{-6}$ in both cell lines, and several clones were isolated from each cell line.

**Characteristics of EGF-Resistant Variants from NA Cells**

As shown in Fig. 2 A and B, the ER variants, from NA cells, grew in an EGF dose-dependent fashion. The ER variants and parental NA cells showed no difference in their morphology while growing (Fig. 3, A and D). Scatchard plot analysis revealed a decreased level of EGF receptors on their surface as compared with NA cells (Table I). Autophosphorylation of the EGF receptor from membrane preparation indicated a substantial decrease in EGF-responsive protein kinase activity (data not shown), reflecting the decrease in active EGF receptor on their surface.

To examine the reason for the reduced levels of EGF receptor on the cell surface, Southern blot analysis and RNA dot hybridization analysis were performed using the EGF receptor cDNA probe pE7. The ER variants were found to have lost their amplified EGFR gene (Fig. 4 A), accompanied by a decrease in EGF receptor mRNA (Fig. 4 B).

Thus, the mechanism to acquire resistance to EGF-mediated growth inhibition in these variants appears to be through a decrease in EGF receptor level by the loss of the amplified EGFR gene. This situation is similar to the EGF-resistant variants isolated from A431 cells (Gill et al., 1985). However, the ER variants are unique because of their acquired EGF-dependent growth. In contrast, the variants from A431 cells previously reported grew regardless of the presence or absence of EGF (Buss et al., 1982).

**Characteristics of EGF-Resistant Variants from Ca9-22 Cells**

The CER variants were isolated from Ca9-22 cells in the same manner that ER variants were isolated from NA cells. The CER variants in general appeared to have a flatter morphology than the parental cells (Fig. 3, E and G). Many of the variants grew regardless of the presence of EGF but at retarded rate (Fig. 5). EGF resistance was further analyzed in CER-1 cells, the only variant which grew without being affected by EGF.

Scatchard plot analysis revealed higher numbers of EGF receptor in CER-1 cells than in Ca9-22 cells (Table I). Flow cytometric analysis using anti-EGF receptor antibody also demonstrated the increased EGF receptor level on the CER-1 cell surface ($\sim 150\%$ of Ca9-22, Fig. 6 A). Cytoplasmic

**Table I. EGF Receptor Number and Affinity in EGF-Response Variants**

| Cell            | Receptor Number | Dissociation Constant |
|-----------------|-----------------|-----------------------|
|                 | High* | Low*  | Total | $K_{d1}$ | $K_{d2}$ |
|                 |       |        |       | nM      | nM      |
| NA              | 6     | 41     | 47    | 0.4     | 8.3     |
| ER6-7           | 0.4   | 2.6    | 3     | 0.25    | 16      |
| ER11            | 0.5   | 2.5    | 3     | 0.25    | 13      |
| Ca9-22          | 3     | 21     | 24    | 0.3     | 7.0     |
| Ca9-22 (EGF)†   | ND    | 21     | 21(13%)| ND      | 7.0     |
| CER-1           | 4     | 47     | 51    | 0.12    | 5.5     |
| CER-1 (EGF)‡    | ND    | 20     | 20(61%)| ND      | 5.5     |

* The number of high ($K_{d1}$) and low ($K_{d2}$) affinity type EGF receptor was determined by the Scatchard plot analysis.
† Cells were treated with EGF (10 ng/ml) for 10 h before the $[^{35}S]$EGF-binding assay.
‡ Loss of EGF receptor number after EGF treatment.
ND, Not detected.
RNA dot blot analysis indicated a relatively higher level of EGFR gene expression in CER-1 cells (Fig. 7 B). Southern blot analysis, however, did not indicate an increased amount of EGFR gene (Fig. 7 A). No difference on the rate of receptor protein biosynthesis was observed in CER-1 cells compared to Ca9-22 cells (Fig. 8).

Interestingly, cytogenetic analysis and flow cytometric analysis for DNA content indicated an increase in the ploidy of CER-1 cells. Ca9-22 cells are hyperdiploid (mode of chromosome number, 56-57) (Fig. 9 A) with numerous rearranged chromosomes (Fig. 10), whereas CER-1 cells were hypertriploid (mode of chromosome number, 83) (Fig. 9 A). Flow cytometric analysis confirmed the presence of a larger amount of DNA in CER-1 cells than in Ca9-22 (Fig. 9, B and C). Thus, the increase in ploidy could result in an increase in cell volume (and cell surface) in CER-1 cells, which may accompany the increase in receptor number per cell. As shown in Fig. 6 B, flow cytometric analysis demonstrated an increased cell volume in CER-1 cells (~116% of Ca9-22).

**EGF Receptor Phosphorylation**

We have examined the possibility whether the acquired EGF resistance in CER-1 cells correlates with a change in the EGF receptor autophosphorylation. As shown in Fig. 11 A, EGF receptors in both CER-1 and Ca9-22 cells were phosphorylated and their phosphorylation was enhanced by EGF. Phosphopeptide map showed that the phosphorylation of peptide 9 was enhanced by EGF (Fig. 11 B). The phosphorylated amino acid of this peptide was found to be tyrosine (data not shown). Considering the previous observation for A431 cells (Downward et al., 1984), this peptide is likely to correspond to the in vivo autophosphorylation site including the Tyr-1173 residue. Thus, EGF receptors in CER-1...
Figure 4. EGFR gene and its expression in the ER variants. DNA (10 μg) was digested with Hind III, serially diluted, subjected to electrophoresis on an agarose gel (0.8%) and transferred to a nitrocellulose filter. 10⁶ cells were lysed with Triton X-100 containing buffer and centrifuged briefly to separate cytoplasmic and nuclear fractions. Cytoplasmic fractions, containing RNA, were denatured with formalin, serially diluted with 15× SSC and applied directly to a nitrocellulose filter equilibrated with 15× SSC. Hybridization was performed using the EGF receptor cDNA probe pE7. (A) Southern blot analysis. (Lane 1) NA (10 μg); (lane 2) NA (5 μg); (lane 3) NA (2.5 μg); (lane 4) NA (1.25 μg); (lane 5) ERII (10 μg); (lane 6) placenta (10 μg). Size marker used was lambda phage DNA cut with Hind III. (B) RNA dot blot hybridization analysis. (Lane 1) NA; (lane 2) ER11 maintained in the absence of EGF for 2 d.

EGF Internalization and Receptor Down-Regulation

We have examined the possible difference in the internalization and degradation rate of EGF in CER-1 and Ca9-22 cells at 37°C. As shown in Fig. 12, A and B, the amount of [¹²⁵I]EGF associated with the intracellular fraction and membrane fraction of CER-1 cells was lower than Ca9-22 cells despite the elevated EGF receptor levels. Moreover, there was no difference in the secretion rate of degraded EGF (Fig. 12 C). Then, we examined the [¹²⁵I]EGF-binding activity after cells were treated with unlabeled EGF (10 ng/ml) for various periods of time. EGF-binding activity of both cell lines was reduced within 3 h to a similar level and the reduced level was kept for at least 10 h (data not shown). Scatchard plot analysis of the binding data revealed that Ca9-22 cells lost 13% of the total EGF receptors by EGF exposure, whereas CER-1 cells lost 61% of the initial surface receptors (Table 2).

Figure 5. Growth of the CER variants in the presence of EGF. EGF dose-response study and kinetic study were carried out as described in Fig. 2. (A) EGF dose-response study. (A) Ca9-22; (o) CER-1; (A) CER-4; (c) CER-8. (B) Kinetic study. (A) CER-1 in the absence of EGF; (A) in the presence of EGF.

Figure 6. Flow cytometric analysis of relative number of EGF receptors and cell volume in Ca9-22 and CER-1. Cells were incubated with anti-EGF receptor antibody (B4G7) for 40 min at 4°C and then with FITC-conjugated secondary antibody. Analysis was performed on a FACS 440. To determine nonspecific binding of antibodies, cells were first incubated with a nonspecific mouse IgG and then with the secondary antibody. (A) Logarithm of fluorescence intensity. The solid line (—) and dotted line (— — — —) indicate the B4G7 derived fluorescence in Ca9-22 and CER-1, respectively. The broken line (----) and sparsely dotted line (— — — —) indicate nonspecific fluorescence in Ca9-22 and CER-1, respectively. (B) Forward scatter light intensity. The solid line and dotted line indicate the intensity of the forward scatter light of Ca9-22 and CER-1, respectively.

Hirai et al.  EGF Receptor Variants 795
I). The decreased EGF binding after exposure to a limited amount of EGF suggests efficient down-regulation of the receptor. Since EGF receptor gene expression was not affected by EGF (Figs. 7 B and 8), the down-regulation may not be caused by transcriptional or translational control. If the receptor internalization occurs only with bound EGF, CER-1 cells with elevated number of receptors should have more internalized EGF than Ca9-22 cells. However, this was not the case. The receptors internalized from CER-1 cells after EGF exposure were far more than the number expected from EGF-binding assay. Therefore, these results suggest that CER-1 cells down-regulate (or internalize) the unoccupied surface receptors more efficiently than Ca9-22 cells. The down-regulation seen in CER-1 cells may involve a mechanism similar to the negative cooperativity or desensitization of the hormone receptor. Although the exact molecular mechanism must await further investigation, this mechanism may give rise to the EGF-resistance of CER-1 cells without loss of the amplified EGF receptor gene.

Discussion

Addition of EGF to the culture medium at concentrations that are mitogenic for other cell types results in a marked inhibition of A431 cells' growth (Gill and Lazar, 1981; Barnes, 1982). We extended this analysis to other EGF receptor-hyperproducing cell lines of squamous cell carcinoma origin (Yamamoto et al., 1986; Gamou et al., 1988). We found that growth inhibition by EGF is common in EGF receptor-hyperproducing cell lines. The only exception is the pancreatic carcinoma cell line UCVA-1, possessing \( \sim 9 \times 10^5 \) receptors/cell (Gamou et al., 1984) with no EGFR gene amplification (Hunts et al., 1986). The growth of UCVA-1 cells was not affected by EGF under either serum-free or serum-containing conditions. UCVA-1 cells have a decreased rate of metabolic turnover of the EGF receptor, which may be responsible for the increased cell surface receptor level (Gamou and Shimizu, 1987). This novel mechanism, however, may not cause EGF-resistance, since the turnover rate in the presence of EGF was similar to other EGF-sensitive, receptor-hyperproducing cell lines.

To investigate the mechanism of EGF-mediated growth inhibition as well as EGF-mediated growth stimulation, we...
and others have isolated variants displaying alternate responses to EGF (Filmus et al., 1987; Buss et al., 1982; Bravo, 1984; Shimizu et al., 1984; Behzadian and Shimizu, 1985a). In this report, we described two series of variants with altered responses to EGF derived from the receptor-hyperproducing cell lines, NA and Ca9-22. Our results suggest two independent mechanisms by which the variants escape EGF-mediated growth inhibition. One mechanism is the loss of the amplified EGFR gene responsible for EGF receptor-hyperproduction as demonstrated by the ER variants. This type of variant has also been isolated from the epidermoid carcinoma cell line A431 (Gill et al., 1985) and the breast

Figure 10. Karyotype of Ca9-22. The chromosome spread was prepared as described in Fig. 9. Karyotype analysis was carried out after G-band staining. Arrows indicate the rearranged chromosomes.

and others have isolated variants displaying alternate responses to EGF (Filmus et al., 1987; Buss et al., 1982; Bravo, 1984; Shimizu et al., 1984; Behzadian and Shimizu, 1985a). In this report, we described two series of variants with altered responses to EGF derived from the receptor-hyperproducing cell lines, NA and Ca9-22. Our results suggest two independent mechanisms by which the variants escape EGF-mediated growth inhibition. One mechanism is the loss of the amplified EGFR gene responsible for EGF receptor-hyperproduction as demonstrated by the ER variants. This type of variant has also been isolated from the epidermoid carcinoma cell line A431 (Gill et al., 1985) and the breast

Figure 11. EGF receptor phosphorylation in Ca9-22 cells and CER-1 cells. (A) Cells were labeled with [32p]orthophosphate for 60 min and treated with EGF (200 ng/ml) for the last 15 min. Immunoprecipitated EGF receptors were separated on SDS-polyacrylamide gel (7%), followed by autoradiography. (B) EGF receptors were eluted from gel and digested with TPCK-trypsin (50 μg) at 37°C for 24 h. The digests were separated on thin layer plates (20 x 20 cm): (1st) electrophoresis at pH 8.9 in 1% ammonium bicarbonate; (2nd) chromatography in butanol/pyridine/acetic acid/water (15:10:3:12, vol/vol). 32P-labeled Peptides were identified by autoradiography for which exposure time was adjusted to keep cpm x day values constant. The radioactivities loaded on the gels were: (a, 1,814 cpm), (b, 4,653 cpm), (c, 300 cpm), (d, 1,193 cpm). (a and b) Ca9-22 cells; (c and d) CER-1 cells; (a and c) no EGF stimulation; (b and d) after EGF stimulation; (e) a diagram of tryptic phosphopeptides: phosphorylated amino acids contained in each spot were as follows: (1) Serine; (2) Threonine>Serine, Tyrosine; (3) Serine; (4) threonine; (5) Serine; (6) Threonine>Serine; (7) Serine; (8) Serine, (9) Tyrosine.
cancer cell line MDA-468 (Filmus et al., 1987). Resistance of these cells was reported to be stable in the absence of EGF for a long period, and seemed to arise from the loss of a certain rearranged chromosome carrying the amplified EGFR gene (Gill et al., 1985). Cytogenetic analysis revealed that the ER variants commonly lost a certain rearranged chromosome seen in NA cells (Gamou, S., M. Kobayashi, and N. Shimizu, unpublished observation). Thus, the examination of whether the amplified EGFR gene is mapped on the rearranged chromosome may be interesting.

The ER variants grew in a strictly EGF-dependent manner. Although the growth of A431 variants was reported to be stimulated by EGF (Buss et al., 1982), they could also grow in the absence of EGF. ER cells showed a flat morphology in the absence of EGF as if they were in the resting stage. We have not been able to identify the molecular basis for the difference in response to EGF in these cells.

Another unique variant, CER-1 cells, acquired EGF-resistance without the loss of the amplified EGFR gene or receptor kinase activity. This type of variant has not been previously described. In contrast to other variants (Filmus et al., 1987; Gill et al., 1985), CER-1 cells gradually regain the sensitivity to EGF-mediated growth inhibition if they are kept in the absence of EGF for several mo.

We described several characteristics that may be related to the mechanism of EGF-resistance in CER-1 cells. One is the increased cell volume and ploidy. This may allow escape from the growth inhibition by EGF although the relationship of increased cell volume and ploidy to EGF-resistance remains to be elucidated.

Another distinction between CER-1 and parental Ca9-22 cells is the efficient EGF receptor down-regulation which is disjoined from EGF internalization in the variant. This seemed to include receptor desensitization to the ligand. The mechanism of down-regulation reduced the EGF receptor level on the cell surface emulating a loss of the amplified EGFR gene. Thus, this down-regulation may play an important role in uncoupling the excess signals by EGF from the cellular responses.

We previously isolated variants from Swiss-3T3 cells using insulin conjugated with diphtheria toxin A fragment (Miskimins and Shimizu, 1981). One of these variants retained the ability to bind insulin, but accumulated lysosome-like vesicles in their cytoplasm, suggesting an alternative endocytic pathway involved in escaping the cytotoxicity of the chimeric insulin (Miskimins et al., 1981). The alternative endocytic pathway does not appear to be a factor in the present situation because excess accumulation of EGF was not observed in the intracellular fraction of CER-1 cells.

As described above, exclusion of the amplified EGFR gene seems to be the most common mechanism to reduce the EGF receptor level on the cell surface. CER-1 cells may use the down-regulation mechanism instead of losing their EGFR genes because of the possibility that their EGFR genes are rearranged and tightly linked with some gene(s) essential for Ca9-22 cells to survive in vitro. In fact, our karyotype analysis revealed numerous rearranged chromosomes but no intact chromosome 7.

Although the exact mechanism of EGF-resistance remains to be elucidated, these variants will be useful to investigate not only the physiological function of EGF and its receptor, but also the genetic and epigenetic control of EGFR gene expression.

The authors thank Dr. K. Rikimaru for providing squamous cell carcinoma cell lines and Dr. I. Pastan for EGF receptor cDNA probe pE7 and also thank Ms. H. Harigai for her assistance in manuscript preparation.

This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science and Culture, from the Ministry of Health and Welfare, and the Science and Technology Agency, Japan, and by a grant from the National Institutes of Health.

Received for publication 7 December 1987, and in revised form 1 April 1988.

References

Barnes, D. W. 1982. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J. Cell Biol. 93:1-4.

Benn.son, K., and T. Hunter. 1978. Characterization of Rous sarcoma virus src gene products synthesized in vitro. J. Virol. 28:551-566.

Behzadian, M. A., and N. Shimizu. 1985a. Variant of A431 cells isolated by ricin A-conjugated monoclonal antibody directed to EGF receptor: Phosphorylation of EGF receptor and phosphatidylinositol. Somat. Cell Mol. Genet. 11:579-591.

Behzadian, M. A., and N. Shimizu. 1985b. Monoclonal antibody that immunoreacts with a subclass of human receptors for epidermal growth factor. Cell Struct. Funct. 10:219-232.

Bravo, R. 1984. Epidermal growth factor inhibits the synthesis of the nuclear protein cyclin in A431 human carcinoma cells. Proc. Natl. Acad. Sci. USA. 81:4848-4850.

Bravo, R., J. Burckhardt, T. Currau, and R. Müller. 1985. Stimulation and inhibition of growth by EGF in different A431 cell clones is accompanied by the rapid induction of c-fos and c-myc proto-oncogenes. EMBO J. 4:1193-1197.
Buss, J. E., J. E. Kudlow, C. S. Lazar, and G. N. Gill. 1982. Altered epidermal growth factor (EGF)-stimulated protein kinase activity in variant A431 cells with altered growth responses to EGF. Proc. Natl. Acad. Sci. USA. 79: 2574-2578.

Buss, J. E., C. Chouvet, and G. N. Gill. 1984. Comparison of protein phosphorylations in variant A431 cells with different growth responses to epidermal growth factor. J. Cell. Physiol. 119:290-306.

Carpenter, G., and S. Cohen. 1979. Epidermal growth factor. Annu. Rev. Biochem. 48:193–216.

Cohen, S., G. Carpenter, and L. King, Jr. 1980. Epidermal growth factor-receptor-kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem. 255:4834–4842.

Cohen, S., U. Ushiro, C. Stoscheck, and M. Chinkers. 1982. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J. Biol. Chem. 257:1523-1531.

Cowley, G., J. A. Smith, B. Gusterson, F. Hendler, and B. Ozanne. 1984. The mechanism increasing cell surface epidermal growth factor receptor levels on the cell surface. Jpn. J. Cancer Res. (Gann). 77:423-427.

Iwashita, S., and C. F. Fox. 1984. Epidermal growth factor and potent phorbol tumor promoters induce epidermal growth factor receptor phosphorylation in a similar but distinctively different manner in human epidermoid carcinoma A431 cells. J. Biol. Chem. 259:2559–2567.

Kawamoto, T., J. Mendelsohn, A. Le, G. H. Sato, C. S. Lazar, and G. N. Gill. 1985. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J. Biol. Chem. 259:7761-7766.

Lifshitz, A., C. S. Lazar, J. E. Buss, and G. N. Gill. 1983. Analysis of morphology and receptor metabolism in clonal variant A431 cells with differing growth responses to epidermal growth factor. J. Cell. Physiol. 115:235–242.

Lin, C. R., W. S. Chen, W. Kruger, L. S. Stolarsky, W. Weber, R. M. Evans, I. M. Verma, G. N. Gill, and M. G. Rosenfeld. 1984. Expression cloning of human EGF receptor complementary DNA: Gene amplification and three related messenger RNA products in A431 cells. Science (Wash. DC). 224: 843-848.

Maron, R., R. A. Jackson, S. Jacobs, G. Eisenbarth, and C. R. Kahn. 1984. Analysis of the insulin receptor by anti-receptor antibodies and flow cytometry. Proc. Natl. Acad. Sci. USA. 81:7446-7450.

Merlino, G. T., Y.-h. Xu, S. Ishii, A. J. L. Clark, K. Semba, K. Toyoshima, T. Yamamoto, and I. Pastan. 1984. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science (Wash. DC). 224:417-419.

Miskimins, W. K., and N. Shimizu. 1981. Genetics of cell surface receptors for bioactive polypeptides: Variants of Swiss/3T3 fibroblasts resistant to a cytotoxic chimeric insulin. Proc. Natl. Acad. Sci. USA. 78:445-449.

Miskimins, W. K., W. R. Ferris, and N. Shimizu. 1981. Genetics of receptors for bioactive polypeptides: a variant of Swiss/3T3 fibroblasts resistant to a cytotoxic insulin accumulates lysosome-like vesicles. J. Supramol. Str. Cell. Biochem. 16:105-113.

Miskimins, W. K., and N. Shimizu. 1984. Uptake of epidermal growth factor into a lysosomal enzyme-deficient organelle: correlation with cell's mitogenic response and evidence for ubiquitous existence in fibroblasts. J. Cell Physiol. 118:305-316.

Mullaneey, P. F., and P. N. Dean. 1970. The small angle light scattering of biological cells: theoretical considerations. Biophys. J. 10:764-772.

Müller, R., R. Bravo, J. Burckhardt, and T. Curran. 1985. Induction of c-fos gene and protein by growth factors precedes activation of c-myc. Nature (Lond.). 312:716-720.

Sawyer, S. T., and S. Cohen. 1981. Enhancement of calcium uptake and phosvitin inhibition of EGF-stimulated phosvitin turnover by epidermal growth factor in A-431 cells. Biochemistry. 20:6280-6286.

Schechter, Y., L. H. Niswander, J. Schlessinger, and P. Cuatrecasas. 1979. Local aggregation of hormone-receptor complexes is required for activation by epidermal growth factor. Nature (Lond.). 278:835-838.

Schlessinger, J., Y. Schechter, M. C. Willingham, and I. Pastan. 1978. Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells. Proc. Natl. Acad. Sci. USA. 75:2659-2663.

Shimizu, N., Y. Shimizu, and W. K. Miskimins. 1984. EGF-receptor C- and ligand C-conjugates: Kinetic profiles of cytotoxic effects and resistant cell variants. Cell Struct. Funct. 9:203-212.

Ulrich, A., L. Coussens, J. S. Hayflick, T. J. Dull, A. Gray, A. W. Tam, J. Lee, Y. Yarden, T. A. Libermann, J. Schlessinger, J. Downward, E. L. V. Mayes, N. Whitle, M. D. Waterfield, and P. H. Seeburg. 1984. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond.). 309:418-425.

White, B. A., and C. Bancroft. 1982. Cytoplasmic dot hybridization: Simple analysis of relative mRNA levels in multiple small cell or tissue samples. J. Biol. Chem. 257:8569-8572.

Yamamoto, T., N. Kamata, H. Kawano, S. Shimizu, T. Kuroki, K. Toyoshima, K. Kikumoto, N. Noma, R. Ishikawa, I. Pastan, S. Gamou, and N. Shimizu. 1986. High incidence of amplification of the epidermal growth factor gene in human squamous carcinoma cell lines. Cancer Res. 46:414-416.